Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Rhea-AI Summary

Bellicum Pharmaceuticals (NASDAQ:BLCM) will report its fourth quarter and full year 2020 financial results on March 30, 2021, after U.S. market close. The management team will host a webcast and conference call at 5 p.m. ET to discuss these results. Bellicum focuses on developing controllable cell therapies for cancer treatment, specifically its GoCAR-T^® candidates, BPX-601 and BPX-603. More details will be accessible on their website after the event.

Positive

• Upcoming financial results may show progress in clinical development and investor interest.
• Management will provide a corporate update during the conference call.

Negative

• None.

Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT

HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the fourth quarter and full year 2020 after the close of U.S. markets on Tuesday, March 30, 2021. Management will host a webcast and conference call at 5 p.m. ET / 2 p.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-407-3103 (U.S. domestic) and 201-493-6791 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investors & Media section of the Bellicum website following the call.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T^® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com

FAQ

When will Bellicum Pharmaceuticals report its financial results for 2020?

Bellicum Pharmaceuticals will report its financial results for the fourth quarter and full year 2020 on March 30, 2021.

What time is the conference call for Bellicum Pharmaceuticals' financial results?

The conference call will take place at 5 p.m. ET / 2 p.m. PT on March 30, 2021.

How can I access the webcast for Bellicum Pharmaceuticals' financial results?

You can access the webcast live through the Events & Presentations section of Bellicum's website.

What products is Bellicum Pharmaceuticals currently developing?

Bellicum Pharmaceuticals is developing controllable cell therapies, specifically its GoCAR-T® product candidates, BPX-601 and BPX-603.

Where can I find more information about Bellicum Pharmaceuticals?

More information about Bellicum Pharmaceuticals can be found on their official website.